# Cholecalciferol

·	Cholecakiferol					
HO HO						
	<u>IUPAC name</u> (3β,5Z,7E)-9,10-secocholesta- 5,7,10(19)-trien-3-ol					
Other names $\frac{\text{vitamin}}{\text{Vitamin}} D_3$ , activated 7-dehydrocholesterol.						
	Identifiers					
CAS number		67-97-0				
<u>PubChem</u>		<u>5280795</u>				
ChemSpider		4444353				
<u>UNII</u>		1C6V77QF41				
EC number						
DrugBank		DB00169				
<u>ChEBI</u>						
<u>ChEMBL</u>		CHEMBL1042				
	ATC code A11CC05					
Jmol-3D images	<u>Image 1</u>					
	<u>SMILES</u>					

 $O[C@@H]1CC(\c(=C)CC1)=C\c(=C2/CCC[C@]3([C@H]2CC[C@@H]3[C@H](C)CCCC(C)C)C$ 

#### **InChI**

InChI=1S/C27H44O/c1-19(2)8-6-9-21(4)25-15-16-26-22(10-7-17-27(25,26)5)12-13-23-18-24(28)14-11-20(23)3/h12-13,19,21,24-26,28H,3,6-11,14-18H2,1-2,4-5H3/b22-12+,23-13-/t21-,24+,25-,26+,27-/m1/s1

Key: QYSXJUFSXHHAJI-YRZJJWOYSA-N

InChI=1/C27H44O/c1-19(2)8-6-9-21(4)25-15-16-26-22(10-7-17-27(25,26)5)12-13-23-18-24(28)14-11-20(23)3/h12-13,19,21,24-26,28H,3,6-11,14-18H2,1-2,4-5H3/b22-12+,23-13-/t21-,24+,25-,26+,27-/m1/s1

lolecular formula	<u>a</u>	C <sub>27</sub> H <sub>44</sub> O
<u>Aolar mass</u>	Form Vin Mouth pissolving	384.64 g/mol
Appearance	Methylcobalamine 1500 mcg + Folic Acid 5 mg + Pyridoxine 3 mg + VitaminD3 1000 I.U. Tablet	White, needle-like crystals
Melting point		83–86 °C
Boiling point		496.4 °C

**Cholecalciferol** (also known as toxiferol  $\frac{[citation \, needed]}{D_3}$ ) is a form of  $\frac{vitamin \, D}{vitamin \, D}$ , also called  $\frac{vitamin \, D}{vitamin \, D}$ , also called  $\frac{vitamin \, D}{vitamin \, D}$ 

It is structurally similar to <u>steroids</u> such as <u>testosterone</u>, <u>cholesterol</u>, and <u>cortisol</u> (though vitamin D<sub>3</sub> itself is a secosteroid).

#### **Forms**

Vitamin D<sub>3</sub> has several forms:

Key: QYSXJUFSXHHAJI-YRZJJWOYBL

- Cholecalciferol (sometimes called calciol) is an inactive, unhydroxylated form of vitamin D<sub>3</sub>).
- Calcifediol (also called calcidiol, hydroxycholecalciferol, 25-hydroxyvitamin D<sub>3</sub>, etc. and abbreviated 25(OH)D) is one of the forms measured in the blood to assess vitamin D status. [3]
- <u>Calcitriol</u> (also called 1,25-dihydroxyvitamin D<sub>3</sub>) is the active form of D<sub>3</sub><sup>[4]</sup>

# Metabolism

<u>7-Dehydrocholesterol</u> is the precursor of vitamin  $D_3$ . Within the epidermal layer of skin, <sup>[5]</sup> 7-Dehydrocholesterol undergoes an <u>electrocyclic reaction</u> as a result of UVB radiation, resulting in the opening of the vitamin precursor B-ring through a <u>conrotatory</u> pathway. Following this, the

previtamin  $D_3$  undergoes a [1,7] antarafacial <u>sigmatropic</u> rearrangement  $\frac{[6]}{}$  and therein finally isomerizes to form vitamin  $D_3$ .

Cholecalciferol is then <u>hydroxylated</u> in the <u>liver</u> to become <u>calcifediol</u> (25-hydroxyvitamin D<sub>3</sub>).

Next, <u>calcifediol</u> is again hydroxylated, this time in the <u>kidney</u>, and becomes <u>calcitriol</u> (1,25-dihydroxyvitamin  $D_3$ ). Calcitriol is the most active hormone form of vitamin  $D_3$ .

#### Regulation of metabolism

- Cholecalciferol is synthesized in the skin from 7-dehydrocholesterol under the action of
  ultraviolet B light. It reaches an equilibrium after several minutes depending on several
  factors including conditions of sunlight (latitude, season, cloud cover, altitude), age of skin,
  and color of skin.
- Hydroxylation in the endoplasmic reticulum of <u>liver hepatocytes</u> of cholecalciferol to calcifediol (25-hydroxycholecalciferol) by <u>25-hydroxylase</u> is loosely regulated, if at all, and blood levels of this molecule largely reflect the amount of vitamin D<sub>3</sub> produced in the skin or the vitamin D<sub>2</sub> or D<sub>3</sub> ingested.
- Hydroxylation in the kidneys of calcifediol to calcitriol by 1-alpha-hydroxylase is tightly regulated (stimulated by either parathyroid hormone or hypophosphatemia) and serves as the major control point in production of the most active circulating hormone calcitriol (1,25-dihydroxyvitamin D<sub>3</sub>).

# Industrial production ine 1500 mcg + Folic Acid 5 mg +

Cholecalciferol is produced industrially for use in vitamin supplements and to fortify foods by the ultraviolet irradiation of <u>7-dehydrocholesterol</u> extracted from <u>lanolin</u> found in sheep's wool. Paraphrasing a more detailed explanation, <sup>[7]</sup> <u>cholesterol</u> is extracted from wool grease and wool wax alcohols obtained from the cleaning of wool after shearing. The cholesterol undergoes a four step process to make 7-dehydrocholesterol, the same compound that is stored in the skin of animals. The 7-dehydrocholesterol is then irradiated with ultra violet light. Some unwanted <u>isomers</u> are formed during irradiation. These are removed by various techniques, leaving a resin which melts at about room temperature and usually has a potency of 25,000,000 to 30.000.000 International Units per gram.

Cholecalciferol is also produced industrially for use in vitamin supplements from  $\frac{\text{lichens}}{\text{lichens}}$ , which is suitable for vegans.

An alternative compound is  $\underline{\text{ergocalciferol}}$  (also known as vitamin  $D_2$ ) derived from the fungal sterol  $\underline{\text{ergosterol}}$ .

#### Dose

One gram is 40,000,000 (40x10<sup>6</sup>) IU, equivalently 1 IU is 0.025 μg.

Recommendations vary depending on the country. In the US they are: 15  $\mu$ g/d (600 IU per day) for all individuals (males, female, pregnant/lactating women) under the age of 70 years-old. For all individuals older than 70 years, 20  $\mu$ g/d (800 IU per day) is recommended. (Recommendations in Europe: 5  $\mu$ g/d, in France: 25  $\mu$ g) A growing body of researchers question whether the current recommended adequate levels are sufficient to meet physiological needs, particularly for individuals deprived of regular sun exposure or those at higher risk such as those with higher melanin content in the skin (i.e., those whose ancestors are

African, Middle Eastern, Latin American, Mediterranean or Asian), the obese, and those who live far from the equator. The upper limit (UL) for vitamin D has been recommended as 4,000 IU daily. The 4,000-IU cut-off was determined by the Institute of Medicine in 2010 after reviewing the then-current medical literature, finding that the dose for lowest observed adverse effect level is 40,000 IU daily for at least 12 weeks, [11] and that there was a single case of toxicity above 10,000 IU after more than 7 years of daily intake; this case of toxicity occurred in circumstances that have led other researchers to dispute it as a credible case to consider when making vitamin D intake recommendations. [11] The Institute of Medicine did not find evidence of toxicity between 4,000 IU and 10,000 IU, so the 4,000-IU figure is more of an estimate than a number based on evidence of toxicity above 4,000 IU. [10] Patients with severe vitamin D deficiency will require treatment with a loading dose; its magnitude can be calculated based on the actual serum 25-hydroxy-vitamin D level and body weight. [12]

Also, there is a therapy for <u>rickets</u> utilizing a single dose, called *stoss* therapy in Europe, taking from 300,000 IU (7,500  $\mu$ g) to 500,000 IU (12,500  $\mu$ g = 1.25 mg), in a single dose, or in two to four divided doses. [13]

The 25-hydroxy vitamin D (<u>calcifediol</u>) blood test is used to determine how much vitamin D is in the body. The normal range of calcifediol is 30.0 to 74.0 ng/ml. [3]

"Vitamin D2 toxicity can result from regular excess intake of this vitamin, and may lead to hypercalcemia and excess bone loss. Individuals at particular risk include those with <a href="https://hyperparathyroidism">hyperparathyroidism</a>, <a href="https://kidney.com/kidney

There are conflicting reports concerning the absorption of cholecalciferol ( $D_3$ ) versus <u>ergocalciferol</u> ( $D_2$ ), with some studies suggesting less efficacy of  $D_2$ , <sup>[15]</sup> and others showing no difference. <sup>[16]</sup> At present,  $D_2$  and  $D_3$  doses are frequently considered interchangeable, but more research is needed to clarify this.

# Stability

Cholecalciferol is very sensitive to <u>UV radiation</u> and will rapidly, but reversibly, break down to form sura-sterols, which can further irreversibly convert to ergosterol

# Preventative application

A 2008 study published in Cancer Research has shown the addition of vitamin  $D_3$  (along with calcium) to the diet of some mice fed a regimen similar in nutritional content to a new Western diet with 1000 IU cholecaliferol per day prevented colon cancer development. In humans, with 400 IU daily, there was no effect; however, significant correlation exists between low levels of blood serum cholecalciferol and higher rates of various cancers, multiple sclerosis, tuberculosis, heart disease, and diabetes.

Objecting the conclusions of the results of recent randomized clinical trials (RCTs), which used "low dose, lack of compliance, cross-over, and poor follow-up" and had concluded that Vitamin D supplementation is unnecessary for most people, Dr. Ed Gorham from the UCSD Department of Family and Preventive Medicine: "Many epidemiologic advances have been based on observational studies. It is fortunate we didn't rely on RCTs to recognize the hazards of cigarette smoking or second-hand smoke, which were determined through case-control studies and cohort studies respectively. To his undying credit, Dr. John Snow did not resort to forcing some residents of Broadstreet to drink from that pump supplying water contaminated by cholera. Do

our ethics allow us to withhold vitamin D to only 800 IU in a placebo group such as that of VITAL? 800 IU would on average raise baseline serum vitamin D levels barely 8 ng/ml. VITAL will place half the participants at risk of what is finally becoming regarded by vitamin D experts as the vitamin D deficiency syndrome. Likewise, the meager 2,000 IU per day given to the treatment group in Vital will still fall short of many of the benefits of vitamin D sufficiency which become apparent when patients achieve a 40-60ng/ml 25(OH)D range."

# **Toxicity**

Rodents are somewhat more susceptible to high doses than other species, and cholecalciferol has been used in poison bait for the control of these pests. It has been claimed that the compound is less toxic to non-target species. However, in practice it has been found that use of cholecalciferol in rodenticides represents a significant hazard to other animals, such as dogs and cats. "Cholecalciferol produces hypercalcemia, which results in systemic calcification of soft tissue, leading to renal failure, cardiac abnormalities, hypertension, CNS depression, and GI upset. Signs generally develop within 18-36 hr of ingestion and can include depression, anorexia, polyuria, and polydipsia."[20]

In New Zealand, possums have become a significant pest animal, and cholecalciferol has been used as the active ingredient in lethal gel baits and cereal pellet baits "DECAL" for possum control. The LD<sub>50</sub> is 16.8 mg/kg, but only 9.8 mg/kg if calcium carbonate is added to the bait.  $\frac{[21][22]}{[23]}$ 

Kidneys and heart are target organs. [23]

#### See also

- Hypervitaminosis D, Vitamin D poisoning
- Ergocalciferol, vitamin D<sub>2</sub>.
- 25-Hydroxyvitamin D3 1-alpha-Hydroxylase, a kidney enzyme that converts calcifediol to calcitriol.

Pyridoxine 3 mg + VitaminD3 1000 I.U. Tablet

# References

- March 2010.

  A "choleoacidieno" at *Dorland's Medical Dictionary*A "25-hydroxy vitamin D test: Mediline Plus". Retrieved 21 March 2010.

  A "Sebendary of Medicine (US) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium; Ross AC, Taylor CL, Yaktine AL, et al., editors. Dietary Reference Intakes for Calcium and Vitamin D. Available from: http://www.ncbi.nlm.nih.gov/books/NBK56061/

  A horman, Anthory W, (1998) Suniplan, Season, skip ingermentation, vitamin D. and 25-hydroxy/stamin Dintegral components of the vitamin D endocrine system. Am J Clin Nutr;67:1108-10.

  Cokamura, W. H., Elnagar, H. Y., Ruther, M. & S. Dobreff. (1993). "Thermal [1,7]-signatropic shift of previtamin D<sub>3</sub> to vitamin D<sub>3</sub> synthesis and study of pentadeuterio derivatives". *Journal of Organic Chemistry* 58 (3): 600-610. doi: 10.1002/j.jo00055a011.

  Vitamin D3 Story, Retrieved 8 April 2012.

  Vitamin D3 Story, Retrieved 8 April 2012.

  Ting Wang, Goran Bengtisson, Indour Kannelant Leave Cultificant

  Time Wang, Goran Bengtisson, Indour Kannelant Leave Cultificant

  Time

- A Vitamin D3 Story, Retrieved 8 April 2012.

  \*Vitashine Vegan Vitamin D3 Supplements\*. Retrieved 2013-03-15.

  \*Ting Wang, Göran Bengtsson, Ingvar Karmeleit, Lars Olof Björn (Sep 1, 2001). "Provitamins and vitamins D, and D, in Cladina spp. over a latitudinal gradient: possible correlation with UV levels\*. J Photochem Photobiol B. (Department of Plant physiology, Lund University, Sweden) 62 (1–2). 118–22. doi:10.1016/s1011-1344(01)00160-39. Retrieved 2013-03-15.

  \*\*2 DRIs for Calcium and Vitamin D

  \*\*2 DRIs for Calcium and Vitamin D

  \*\*A PRIS for Calcium and Vitamin D

  \*\*supplementation, 25-hydroxyvitamin D concentrations, and safety\*. Am. J. Clin. Nutr. 69 (5): 842–56. PMID 10:232622.

  \*\*van Groningen L, Opdenorott S, van Sorge A, Tellting D, Giesen A, de Boer H (April 2010). "Cholecalciferol [pading dose] guideline for vitamin D-deficient adults\*. Eur. J. Endocrinol. 162 (4): 805–

  \*\*A bland 4620/ELE 00.0032 PMID 20130241
- . doi:10.1530/EJE-09-0932. PMID 20139241.
  Shah BR, Finberg L (September 1994). "Single-day therapy for nutritional vitamin D-deficiency rickets: a preferred method". J. Pediatr. 125 (3): 487-90. doi:10.1016/S0022-3476(05)83303-
- NIMID 80/TIGH. Supplements with the National Academy of Sciences dosing recommendations at the Medline Plus website.


  Armas LA, Hollis BW, Heaney RP (November 2004). "Vitamin D2 is much less effective than vitamin D3 in humans". J. Clin. Endocrinol. Metab. 89 (11): 5387–91. doi:10.1210/jc.2004-
- 16.
- OSS. PMD 15531486.
  A Holick MF, Blancuzzo RM, Chen TC, Klein EK, Young A, Bibuld D, Reitz R, Salarneh W, Ameri A, Tannenbaum AD (March 2008). "Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D². J. Clin. Endocrinol. Metab. 93 (3): 677–81. doi:10.1210/jc.2007-2308. PMC 2266966. PMD 15093991.
  A Yang K, Kurhara N, Fan K, Newmark H, Rigas B, Bancroft L, Comer G, Livote E, Lesser M, Edelmann W, Velcich A, Lipkin M, Augenlicht L (October 2008). "Dietary induction of colonic tumors in a mouse model of sporadic colon cancer". Cancer Res. 68 (19): 7803–10. doi:10.1150/jc.2007-2308. PMC 2266966. PMD 15093991.
  A Yang K, Kurhara N, Fan K, Newmark H, Rigas B, Bancroft L, Comer G, Livote E, Lesser M, Edelmann W, Velcich A, Lipkin M, Augenlicht L (October 2008). "Dietary induction of colonic tumors in a mouse model of sporadic colon cancer". Cancer Res. 68 (19): 7803–10. doi:10.1150/jc.2007-2308. PMC 2266966. PMD 15093991.
  A Wacatawski-Wende J, Kotchen JM, Anderson GL, Assaf AR, Brunner RL, O'Sullivan MJ, Margolis KL, Ockene JK, Phillips L, Potentic RL, Robbirs J, Rohan TE, Sarto GE, Sharma S, Stefanick ML, Van Horn L, Wallace RB, Whiltouc E, Bassford T, Beresford SA, Black HR, Bonds DE, Brzyski RG, Caane B, Chlebowski RT, Cochrane B, Garland C, Gass M, Hays J, Heiss G, Hendrix SL, Howard BV, Hsia J, Hubbell FA, Jackson RD, Johnson KC, Judd H, Kooperberg CL, Kuller LH, LaCroix AZ, Lane DS, Langer RD, Lasser NL, Lewis CE, Limacher MC, Manson JE (February 2006). "Calcium plus vitamin D supplementation and the risk of colorectal cancer". N Engl J. Med. 354 (19): 684–985. doi:10.1056/NEJMond555222. PMID 16481638.
  A Cediric F. Garland, DrPH, Frank C. Garland, PhD, Edward D. Gomm, PhD, MPH, Martin Lipkin, MD, Harold Newmark, ScD, Sharif B. Mohr, MPH, and Michael F. Holick, MD, PhD (February 2006). "The Robe of Vitamin D in Cancer Prevention". Am J Public Health Sc5–261. doi:10.1056/NEJMond55922. PMID 16481638.
  A "Merck Veterinary Manual Rodenticide Poisoning: Introduction".

- 83. doi:10.1071/WR9950579.

  \* "Kiwicare Material Safety Data Sheet".

# Folic acid

#### Folio ocid





#### **IUPAC** name

#### Other names

 $\label{eq:N-(4-{leading-4-oxo-1,4-dihydropteridin-6-yl)} N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}) benzoyl)-L-glutamic acid; pteroyl-L-glutamic acid; Vitamin B<math>_{\rm e}$ ; Folacin

#### Identifiers

<u>CAS number</u>	59-30-3
<u>PubChem</u>	6037
<u>ChemSpider</u>	<u>5815</u>
<u>UNII</u>	935E97BOY8

<u>DrugBank</u>	DB00158
<u>KEGG</u>	<u>C00504</u>
<u>ChEBI</u>	CHEBI:27470
<u>ChEMBL</u>	CHEMBL1622
RTECS number	LP5425000
ATC code	B03BB01
<u>Jmol</u> -3D images	Image 1

#### **SMILES**

O = C(N[C@H](C(O) = O)CCC(O) = O)C1 = CC = C(NCC2 = NC(C(NC(N) = N3) = O) = C3N = C2)C = C1

#### **InChI**

InChI=1S/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s1

Key: OVBPIULPVIDEAO-LBPRGKRZSA-N

InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s1

Key: OVBPIULPVIDEAO-LBPRGKRZBH

Properties	
Molecular formula	C <sub>19</sub> H <sub>19</sub> N <sub>7</sub> O <sub>6</sub>
Molar mass	441.40 g mol <sup>-1</sup>
Appearance	yellow-orange crystalline powder
Melting point	250 °C (523 K) (decomposition) [11]
Solubility in water	1.6 mg/L (25 °C) <sup>[]]</sup>
log P	-2.5
Acidity (p $K_a$ )	1st: 4.65, 2nd: 6.75, 3rd: 9.00 <sup>[2]</sup>
	100 100, 21d. 075, 31d. 7.00

Hazards

# NFPA 704 Q 1 Q Except where noted otherwise, data are given for materials in their standard state (at 25 °C (77 °F), 100 kPa)

Folic acid (also known as vitamin M, vitamin  $B_9$ , [3] vitamin  $B_c$  (or folacin), pteroyl-<u>L-glutamic acid</u>, and pteroyl-<u>L-glutamate</u>) [dubious - discuss] is a form of thewater-soluble vitamin  $\underline{B}_9$ . [5] Folate is a naturally occurring form of the vitamin, found in food, while folic acid is synthetically produced, and used in fortified foods and supplements. [6] Folic acid is itself not biologically active, but its biological importance is due to tetrahydrofolate and other derivatives after its conversion to dihydrofolic acid in the liver. [7]

Vitamin  $B_9$  (folate converted from folic acid) is <u>essential</u> for numerous <u>bodily functions</u>. Humans cannot synthesize folate <u>de novo</u>; therefore, folate has to be supplied through the diet to meet their daily requirements. The human body needs folate to synthesize DNA, repair DNA, and <u>methylate</u> DNA as well as to act as a cofactor in certain biological reactions. [8] It is especially important in aiding rapid <u>cell division</u> and <u>growth</u>, such as in infancy and pregnancy. <u>Children</u> and <u>adults</u> both require folate to <u>produce</u>healthy <u>red blood cells</u> and prevent anemia. [9]

Folate and folic acid derive their names from the <u>Latin</u> word <u>folium</u>, which means "leaf". Folate occurs naturally in many foods and, among plants, are especially plentiful in dark green leafy vegetables. [10]

A lack of <u>dietary</u> folates can lead to <u>folate deficiency</u>. A complete lack of dietary folate takes months before deficiency develops as normal individuals have about 500–20,000 µg<sup>[11]</sup> of folate in body stores. This deficiency can result in many health problems, the most notable one being <u>neural tube defects</u> in developing embryos. Common symptoms of <u>folate</u> <u>deficiency</u> include <u>diarrhea</u>, <u>macrocytic anemia</u> with weakness or shortness of breath, nerve damage with weakness and limb numbness (<u>peripheral neuropathy</u>), pregnancy complications, mental confusion, forgetfulness or other cognitive deficits, mental depression, sore or swollen tongue, peptic or mouth ulcers, headaches, heart palpitations, irritability, and behavioral disorders. Low levels of folate can also lead to <u>homocysteine</u> accumulation. DNA synthesis and repair are impaired, which could lead to cancer development.

## Health benefits and risks

#### **Pregnancy**

Adequate folate intake during the preconception period (which is the time right before and just after a woman becomes pregnant) helps protect against a number of congenital malformations, including neural tube defects (which are the most notable birth defects that occur from folate deficiency). Neural tube defects are severe abnormalities of the central nervous system that develop in babies during the first few weeks of pregnancy resulting in malformations of the spine, skull, and brain; the most common neural tube defects are spina bifida and anencephaly. The risk of neural tube defects is significantly reduced when supplemental folic acid is consumed in addition to a healthy diet before conception and during the first month after conception. Supplementation with folic acid has also been shown to reduce the risk of congenital heart defects, cleft lips, lift limb defects, and urinary tract anomalies.

deficiency during pregnancy may also increase the risk of preterm delivery, infant low birth weight and fetal growth retardation, as well as increasing homocysteine level in the blood, which may lead to spontaneous abortion and pregnancy complications, such asplacental abruption and pre-eclampsia. [19] Women who could become pregnant are advised to eat foods fortified with folic acid or take supplements in addition to eating folate-rich foods to reduce the risk of serious birth defects. [20] Taking 400 micrograms of synthetic folic acid daily from fortified foods and/or supplements has been suggested for all non-pregnant women, in order to have adequate folic acid intake even in case of unplanned pregnancies. [21] The RDA for folate equivalents for pregnant women is set at 600 micrograms, [22] although a range of 400 micrograms up to 4 milligrams (4000 micrograms) reported in an old U.S. Public Health Service guideline is still followed by many health care providers. [21][23][24][25] The mechanisms and reasons why folic acid prevents birth defects is unknown. [26] It is hypothesized that the insulin-like growth factor 2 gene is differentially methylated and these changes in IGF2 result in improved intrauterine growth and development. [26] Approximately 85% of women in an urban Irish study reported using folic acid supplements before they become pregnant, but only 18% used enough folic acid supplements to meet the current folic acid requirements due, it is reported, to socioeconomic challenges. [27] Folic acid supplements may also protect the fetus against disease when the mother is battling a disease or taking medications or smoking during pregnancy. [28]

It also contributes to <u>oocyte maturation</u>, <u>implantation</u>, <u>placentation</u>, in addition to the general effects of <u>folic acid and pregnancy</u>. Therefore, it is necessary to receive sufficient amounts through the diet to avoid <u>subfertility</u>. [29]

There is growing concern worldwide that prenatal high folic acid in the presence of low vitamin B12 causes epigenetic changes in the unborn predisposing them to metabolic syndromes, central adiposity and adult diseases such as Type 2 diabetes. Another active area of research and concern is that either too much or too little folic acid in utero causes epigenetic changes to the brain leading to autism spectrum disorders. [31][32][33]

#### **Fertility**

Folate is necessary for <u>fertility</u> in both men and women. It contributes to <u>spermatogenesis</u>. Therefore, it is necessary to receive sufficient amounts through the diet to avoid<u>subfertility</u>. Also, polymorphisms in genes of enzymes involved in folate metabolism could be one reason for fertility complications in some women with unexplained infertility. [34]

#### **Heart disease**

Taking folic acid does not reduce cardiovascular disease even though it reduces <u>homocysteine</u> levels. [35]

Folic acid supplements consumed before and during pregnancy may reduce the risk of heart defects in infants.  $\frac{[36]}{}$ 

#### Stroke

Folic acid appears to reduce the risk of stroke, which may be due to the role folate plays in regulating homocysteine concentration. The reviews indicate the risk of stroke appears to be reduced only in some individuals, but a definite recommendation regarding supplementation beyond the current RDA has not been established for stroke prevention. Observed stroke reduction is consistent with the reduction in <u>pulse pressure</u> produced by folate supplementation of 5 mg per day, since hypertension is a key risk factor for stroke. Folic supplements are inexpensive and relatively safe to use, which is why stroke or <u>hyperhomocysteinemia</u> patients are encouraged to consume daily B <u>vitamins</u> including folic acid.

#### Cancer

Folic acid supplementation does not appear to affect the rate of cancer. [39][40]

Diets high in folate are associated with decreased risk of <u>colorectal cancer</u>; some studies show the association is stronger for folate from foods alone than for folate from foods and supplements, [41] One broad cancer screening trial reported a potential harmful effect of too much folate intake on breast cancer risk, suggesting routine folate supplementation should not be

recommended as a breast cancer preventive.  $^{[42]}$  Most research studies associate high dietary folate intake with a reduced risk of prostate cancer.  $^{[43]}$ 

#### **Antifolates**

Folate is important for cells and tissues that rapidly divide. [44] Cancer cells divide rapidly, and drugs that interfere with folate metabolism are used to treat cancer.

The <u>antifolate</u> <u>methotrexate</u> is a drug often used to treat cancer because it inhibits the production of the active form of THF from the inactive dihydrofolate (DHF). However, methotrexate can be toxic. [45][46][47] producing side effects, such as inflammation in the digestive tract that make it difficult to eat normally. Also, bone marrow depression (inducing leukopenia and thrombocytopenia), and acute renal and hepatic failure have been reported.

Folinic acid, under the drug name leucovorin, a form of folate (formyl-THF), can help "rescue" or reverse the toxic effects of methotrexate. Folinic acid is not the same as folic acid. Folic acid supplements have little established role in cancer chemotherapy. There have been cases of severe adverse effects of accidental substitution of folic acid for folinic acid in patients receiving methotrexate cancer chemotherapy. It is important for anyone receiving methotrexate to follow medical advice on the use of folic or folinic acid supplements. The supplement of folinic acid in patients undergoing methotrexate treatment is to give cells dividing less rapidly enough folate to maintain normal cell functions. The amount of folate given will be depleted by rapidly dividing cells (cancer) very quickly and so will not negate the effects of methotrexate.

Methylcobalamine 1500 mcg + Folic Acid 5 mg + Psychological Pyridoxine 3 mg + VitaminD3 1000 I.U. Tablet

Some evidence links a shortage of folate with depression. [51] Limited evidence from randomised controlled trials showed using folic acid in addition to SSRIs may have benefits. [52] Research at the University of York and Hull York Medical School has found a link between depression and low levels of folate. [53] One study by the same team involved 15,315 subjects. [54] However, the evidence is probably too limited at present for this to be a routine treatment recommendation. [according to whom?] Folic acid supplementation

affects <u>noradrenaline</u> and <u>serotonin</u> receptors within the brain, which could be the cause of folic acid's possible ability to act as an antidepressant. [55][56] The exact mechanisms involved in the development of schizophrenia are not entirely clear, but may have something to do with DNA methylation and one carbon metabolism, and these are the precise roles of folate in the body. [57]

#### **Macular degeneration**

A substudy of the Women's Antioxidant and Folic Acid Cardiovascular Study published in 2009 reported use of a nutritional supplement containing folic acid, pyridoxine, and cyanocobalamin decreased the risk of developing age-related macular degeneration by 34.7%.<sup>[58]</sup>

#### Folic Acid, B<sub>12</sub> and Iron

There is a complex interaction between folic acid, vitamin B<sub>12</sub> and iron. A deficiency of one may be "masked" by excess of another so the three must always be in balance. [59][60][61]

#### **Toxicity**

The risk of toxicity from folic acid is low, because folate is a water-soluble vitamin and is regularly removed from the body through urine. 62 One potential issue associated with high dosages of folic acid is that it has a masking effect on the diagnosis of <u>pernicious anaemia</u> (vitamin B<sub>12</sub> deficiency), [25] and a variety of concerns [clarification needed] of potential negative impacts on health.[63]

#### Folate deficiency

Main article: Folate deficiency

<u>Folate deficiency</u> may lead to <u>glossitis</u>, diarrhea, depression, confusion, <u>anemia</u>, and fetal <u>neural</u> <u>tube defects</u> and brain defects (during pregnancy). Folate deficiency is accelerated by alcohol

consumption. Folate deficiency is diagnosed by analyzing <u>CBC</u> and plasma vitamin B<sub>12</sub> and folate levels. CBC may indicate megaloblastic anemia but this could also be a sign of vitamin B<sub>12</sub> deficiency. A serum folate of 3  $\mu$ g/L or lower indicates deficiency. Serum folate level reflects folate status but erythrocyte folate level better reflects tissue stores after intake. An erythrocyte folate level of 140  $\mu$ g/L or lower indicates inadequate folate status. Increased homocysteine level suggests tissue folate deficiency but homocysteine is also affected by vitamin B<sub>12</sub> and vitamin B<sub>6</sub>, renal function, and genetics.

One way to differentiate between folate deficiency from vitamin  $B_{12}$  deficiency is by testing for methylmalonic acid levels. [64] Normal MMA levels indicate folate deficiency and elevated MMA levels indicate vitamin  $B_{12}$  deficiency. Folate deficiency is treated with supplemental oral folate of 400 to 1000  $\mu$ g per day. This treatment is very successful in replenishing tissues, even if deficiency was caused by malabsorption. Patients with megaloblastic anemia need to be tested for vitamin  $B_{12}$  deficiency before folate treatment, because if the patient has vitamin  $B_{12}$  deficiency, folate supplementation can remove the anemia, but can also worsen neurologic problems. Morbidly obese patients with BMIs of greater than 50 are more likely to develop folate deficiency. Patients with celiac disease have a higher chance of developing folate deficiency. Cobalamin deficiency may lead to folate deficiency, which, in turn, increases homocysteine levels and may result in the development of cardiovascular disease or birth defects.

# Malaria Methylcobalamine 1500 mcg + Folic Acid 5 mg +

Some studies show iron-folic acid supplementation in children under 5 may result in increased mortality due to <u>malaria</u>; this has prompted the World Health Organization to alter their iron-folic acid supplementation policies for children in malaria-prone areas, such as India. [68]

# Dietary reference intake

Because of the difference in bioavailability between supplemented folic acid and the different forms of folate found in food, the dietary folate equivalent (DFE) system was established. One DFE is defined as 1 µg (microgram) of dietary folate, or 0.6 µg of folic acid supplement.

$\underline{\textbf{National Institutes of Health}}(US)\textbf{Nutritional Requirements}^{\underline{\text{(iii)}}}(\mu g\text{per}\text{day})$								
Age	Infants ( <u>RDI</u> )	Infants ( <u>UL</u> )	Adults (RDI)	Adults (UL)	Pregnant women (RDI)	Pregnant women (UL)	Lactating women (RDI)	Lactating women (UL)
0–6 months	65	None set	-	-	_	_	-	_
7–12 months	80	None set	-	-	-	_	-	_
1–3 years	-	-	150	300	_	_	-	_
4–8 years	-	-	200	400	_	_	-	_
9–13 years	-	-	300	600	-	-	-	-
14–18	-	-	400	800	600	800	500	800
19+	-	-	400	1000	600	1000	500	1000

The <u>Dietary Reference Intake</u> (DRIs) were developed by the <u>United States National Academy of Sciences</u> to set reference values for planning and assessing nutrient intake for healthy people. DRIs incorporate two reference values, the <u>Reference Daily Intake</u> (RDI, the daily intake level that is adequate for 97–98% of the population in the United States where the standards were set) and <u>tolerable upper intake levels</u> (UL, the highest level of intake that is known to avoid toxicity). The UL for folate refers to only synthetic folate, as no health risks have been associated with high intake of folate from food sources. [69]

#### Sources

Folate naturally occurs in a wide variety of foods, including vegetables (particularly dark green <u>leafy vegetables</u>), fruits and fruit juices, nuts, beans, peas, dairy products, poultry and meat, eggs, seafood, grains, and some beers. <a href="fi0l[70]Spinach">[10l[70]Spinach</a>, liver, yeast, asparagus, and Brussels sprouts are among the foods with the highest levels of folate. <a href="fi0l[10]">[10l]</a>

Folic acid is added to grain products in many countries, and in these countries, fortified products make up a significant source of the population's folic acid intake. Because of the difference in bioavailability between supplemented folic acid and the different forms of folate found in food, the dietary folate equivalent (DFE) system was established. 1 DFE is defined as 1  $\mu$ g of dietary folate, or 0.6  $\mu$ g of folic acid supplement. This is reduced to 0.5  $\mu$ g of folic acid if the supplement is taken on an empty stomach.

Folate naturally found in food is susceptible to high heat and ultraviolet light, and is soluble in water. [73] It is heat-labile in acidic environments and may also be subject to oxidation.

Some meal replacement products do not meet the folate requirements as specified by the RDAs.  $^{[74]}$ 

Folate (B9) can also be processed from the pro-vitamin Pteroylmonoglutamic acid (Vitamin B10).

# History

In the 1920s, scientists believed folate deficiency and anemia were the same condition. [75] A key observation by researcher Lucy Wills in 1931 led to the identification of folate as the nutrient needed to prevent anemia during pregnancy. Dr. Wills demonstrated anemia could be reversed with brewer's yeast. Folate was identified as the corrective substance in brewer's yeast in the late 1930s, and was first isolated in and extracted from spinach leaves by Mitchell and others in 1941. [76] Bob Stokstad isolated the pure crystalline form in 1943, and was able to determine its chemical structure while working at the Lederle Laboratories of the American Cyanamid Company. [77] This historical research project, of obtaining folic acid in a pure crystalline form in 1945, was done by the team called the "folic acid boys," under the supervision and guidance of Director of Research Dr. Yellapragada Subbarow, at the Lederle Lab, Pearl River, NY. [78] This research subsequently led to the synthesis of the antifolate aminopterin, the first-ever anticancer drug, the clinical efficacy was proven by Sidney Farber in 1948. In the 1950s and 1960s, scientists began to discover the biochemical mechanisms of action for folate. [75] In 1960, experts first linked folate deficiency to neural tube defects. [75] In the late 1990s, US scientists realized, despite the availability of folate in foods and in supplements, there was still a challenge for people to meet their daily folate requirements, which is when the US implemented the folate fortification program.[75]

# Biological roles

#### **DNA** and cell division

Folate is necessary for the production and maintenance of new <u>cells</u>, for <u>DNA</u> <u>synthesis</u> and <u>RNA synthesis</u>, and for preventing changes to <u>DNA</u>, and, thus, for preventing <u>cancer</u>. It is especially important during periods of frequent cell division and growth, such as infancy and pregnancy. Folate is needed to carry one-carbon groups for methylation reactions and <u>nucleic acid</u> synthesis (the most notable one being thymine, but also <u>purine</u> bases). Thus, folate deficiency hinders DNA synthesis and cell division, affecting

hematopoietic cells and neoplasms the most because of their greater frequency of cell division. RNA transcription, and subsequent protein synthesis, are less affected by folate deficiency, as the mRNA can be recycled and used again (as opposed to DNA synthesis, where a new genomic copy must be created). Since folate deficiency limits cell division, erythropoiesis, production of red blood cells, is hindered and leads to megaloblastic anemia, which is characterized by large immature red blood cells. This pathology results from persistently thwarted attempts at normal DNA replication, DNA repair, and cell division, and produces abnormally large red cells called megaloblasts (and hypersegmented neutrophils) with abundant cytoplasm capable of RNA and protein synthesis, but with clumping and fragmentation of nuclear chromatin. Some of these large cells, although immature (reticulocytes), are released early from the marrow in an attempt to compensate for the <u>anemia</u>. Both adults and children need folate to make normal red and white blood cells and prevent <u>anemia</u>. Deficiency of folate in pregnant women has been implicated in neural tube defects (NTD); therefore, many developed countries have implemented mandatory folic acid fortification in cereals, etc. NTDs occur early in pregnancy (first month), therefore women must have abundant folate upon conception. Folate is required to make red blood cells and white blood cells and folate deficiency may lead to anemia, which further leads to fatigue and weakness and inability to concentrate. [82]

## Biochemistry of DNA base and amino acid production

In the form of a series of <u>tetrahydrofolate</u> (THF) compounds, folate derivatives are <u>substrates</u> in a number of single-carbon-transfer reactions, and also are involved in the synthesis of <u>dTMP</u>(2'-deoxythymidine-5'-phosphate) from <u>dUMP</u> (2'-deoxyuridine-5'-phosphate). It is a substrate for an important reaction that involves <u>vitamin B<sub>12</sub></u> and it is necessary for the synthesis of DNA, and so required for all dividing cells. [18]

The pathway leading to the formation of <u>tetrahydrofolate</u> (FH<sub>4</sub>) begins when folic acid (F) is <u>reduced</u> to <u>dihydrofolate</u> (DHF) (FH<sub>2</sub>), which is then reduced to THF. <u>Dihydrofolate</u> <u>reductase</u>catalyses the last step. [83] Vitamin B<sub>3</sub> in the form of <u>NADPH</u> is a necessary cofactor for both steps of the synthesis. Thus, hydride molecules are transferred from NADPH to the C6 position of the pteridine ring to reduce folic acid to THF. [84]

Methylene-THF (CH<sub>2</sub>FH<sub>4</sub>) is formed from THF by the addition of a <u>methylene bridge</u> from one of three carbon donors: <u>formate</u>, <u>serine</u>, or <u>glycine</u>. <u>Methyl tetrahydrofolate</u> (CH<sub>3</sub>-THF, or methyl-THF) can be made from methylene-THF by reduction of the methylene group with NADPH.

Another form of THF, 10-formyl-THF, results from <u>oxidation</u> of methylene-THF or is formed from formate donating formyl group to THF. Also, histidine can donate a single carbon to THF to form methenyl-THF.

Vitamin  $B_{12}$  is the only acceptor of methyl-THF, and this reaction produces methyl- $B_{12}$  (methylcobalamin). There is also only one acceptor for methyl- $B_{12}$ , homocysteine, in a reaction catalyzed by homocysteine methyltransferase. These reactions are of importance because a defect in homocysteine methyltransferase or a deficiency of  $B_{12}$  may lead to a so-called "methyl-trap" of THF, in which THF is converted to a reservoir of methyl-THF which thereafter has no way of being metabolized, and serves as a sink of THF that causes a subsequent deficiency in folate. Thus, a deficiency in  $B_{12}$  can generate a large pool of methyl-THF that is unable to undergo reactions and will mimic folate deficiency.

The reactions that lead to the methyl-THF reservoir can be shown in chain form:

 $folate \rightarrow dihydrofolate \rightarrow tetrahydrofolate \leftrightarrow methylene-THF \rightarrow methyl-THF$ 

#### Conversion to biologically active derivatives

All the biological functions of folic acid are performed by <u>tetrahydrofolate</u> and other derivatives. Their biological availability to the body depends upon <u>dihydrofolate reductase</u> action in the <u>liver</u>. This action is unusually slow in humans, being less than 2% of that in rats. Moreover, in contrast to rats, an almost-5-fold variation in the activity of this enzyme exists between humans. <sup>[7]</sup> Due to this low activity, it has been suggested this limits the conversion of folic acid into its biologically

active forms "when folic acid is consumed at levels higher than the Tolerable Upper Intake Level (1 mg/d for adults)." [7]

#### Overview of drugs that interfere with folate reactions

A number of drugs interfere with the biosynthesis of folic acid and THF. Among them are the <u>dihydrofolate reductase inhibitors</u> such as <u>trimethoprim</u>, <u>pyrimethamine</u>, and <u>methotrexate</u>; the <u>sulfonamides</u> (competitive inhibitors of <u>4-aminobenzoic acid</u> in the reactions of dihydropteroate synthetase).

<u>Valproic acid</u>, one of the most commonly prescribed anticonvulsants that is also used to treat certain psychological conditions, is a known inhibitor of folic acid, and as such, has been shown to cause <u>neural tube defects</u> and cases of <u>spina bifida</u> and cognitive impairment in the <u>newborn</u>. Because of this considerable risk, those mothers who must continue to use valproic acid or its derivatives during pregnancy to control their condition (as opposed to stopping the drug or switching to another drug or to a lesser dose) should take folic acid <u>supplements</u> under the direction and guidance of their health care providers.

The National Health and Nutrition Examination Survey (NHANES III 1988–91) and the Continuing Survey of Food Intakes by Individuals (1994–96 CSFII) indicated most adults did not consume adequate folate. However, the folic acid fortification program in the United States has increased folic acid content of commonly eaten foods such as cereals and grains, and as a result, diets of most adults now provide recommended amounts of folate equivalents.

# Dietary fortification

See also: Food fortification

Folic acid fortification is a process where folic acid is added to flour with the intention of promoting public health through increasing blood folate levels in the populace. In the USA, food is fortified with folic acid, only one of the many naturally-occurring forms of folate, and a substance contributing only a minor amount to the folates in natural foods. [63]

Since the discovery of the link between insufficient folic acid and <u>neural tube defects</u>, governments and health organizations worldwide have made recommendations concerning folic acidsupplementation for women intending to become pregnant.

Fortification is controversial, with issues having been raised concerning individual liberty,  $^{[63]}$  as well as the health concerns described in the  $\underline{\text{Toxicity}}$  section above. In the USA, there is concern that the federal government mandates fortification, but does not provide monitoring of potential undesirable effects of fortification.  $^{[63]}$ 

76 countries worldwide require mandatory folic acid fortification of at least one major cereal grain, with nearly all fortifying at least wheat flour, according to November 2013 data from the Flour Fortification Initiative. These countries are:

Antigua and Barbuda, Argentina, Australia, Bahamas, Bahrain, Barbados, Belize, Benin, Bolivia (Plurinational State of), Brazil, Burkina Faso, Cameroon, Canada, Chile, Colombia, Costa Rica, Cote d'Ivoire, Cuba, Dominica, Dominican Republic, Ecuador, Egypt, El Salvador, Fiji, Ghana, Grenada, Guatemala, Guinea, Guyana, Haiti, Honduras, Indonesia, Iran (Islamic Republic of), Iraq, Jamaica, Jordan, Kazakhstan, Kenya, Kosovo, Kuwait, Kyrgyzstan, Liberia, Mali, Mauritania, Mexico, Morocco, Nepal, Nicaragua, Niger, Nigeria, Oman, Palestine (Occupied Territory), Panama, Papua New Guinea, Paraguay, Peru, Republic of Moldova, Rwanda, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Saudi Arabia, Senegal, Sierra Leone, Solomon Islands, South Africa, Suriname, Tanzania (United Republic of), Togo, Trinidad and Tobago, Turkmenistan, Uganda, United States of America, Uruguay, Uzbekistan, and Yemen. [88]

As of November 2013, no EU country has mandated folic acid fortification. [88]

#### Australia

There has been previous debate in <u>Australia</u> regarding the inclusion of folic acid in products such as bread and flour. [89]

Australia and New Zealand have jointly agreed to fortification though the Food Standards Australia New Zealand. Australia will fortify all flour from 18 September 2009. Although the food standard covers both Australia and New Zealand, an Australian government official has stated it is up to New Zealand to decide whether to implement it there, and they will watch with interest.

The requirement is 0.135 mg of folate per 100g of bread.

#### Canada

In 2003, a <u>Hospital for Sick Children</u>, <u>University of Toronto</u> research group published findings showing the fortification of flour with folic acid in <u>Canada</u> has resulted in a dramatic decrease in <u>neuroblastoma</u>, an early and very dangerous cancer in young children. [92] In 2009, further evidence from <u>McGill University</u> showed a 6.2% decrease per year in the birth prevalence of severe congenital heart defects. [93]

Folic acid used in fortified <u>foods</u> is a synthetic form called <u>pteroylmonoglutamate</u>. [94] It is in its <u>oxidized</u> state and contains only one <u>conjugated glutamate</u> residue. [94] Folic acid therefore enters via a different carrier system from naturally occurring folate, and this may have different effects on folate binding proteins and its transporters. [95] Folic acid has a higher bioavailability than natural folates and are rapidly absorbed across the intestine, [94] therefore it is important to consider the Dietary Folate Equivalent (DFE) when calculating one's intake. Natural occurring folate is equal to 1 DFE, however 0.6 µg of folic acid is equal to 1 DFE.

Folic acid <u>food fortification</u> became mandatory in <u>Canada</u> in 1998, with the fortification of 150 µg of folic acid per 100 grams of <u>enriched flour</u> and uncooked <u>cereal</u> grains. The purpose of fortification was to decrease the risk of <u>neural tube defects</u> in <u>newborns</u>. It is important to fortify grains because it is a widely eaten food and the neural tube closes in the first four weeks of gestation, often before many women even know they are pregnant. Canada's fortification program has been successful with a decrease of neural tube defects by 19% since its introduction. A seven-province study from 1993 to 2002 showed a reduction of 46% in the overall rate of neural tube defects after folic acid fortification was introduced in Canada. The fortification program was estimated to raise a person's folic acid intake level by 70–130 µg/day, however an increase of almost double that amount was actually observed. This could be from the fact that many foods are over fortified by 160–175% the predicted value. In addition, much of the elder population take <u>supplements</u> that adds 400 µg to their daily folic acid intake. This is a concern because 70–80% of the population have detectable levels of unmetabolized folic acid in their <u>blood</u> and high intakes can accelerate the growth of <u>preneoplasmic lesions</u>. It is still unknown the amount of folic acid supplementation that might cause harm.

#### Supplementation promotion

According to a Canadian survey, 58% of women said they took a folic acid containing multivitamin or a folic acid supplement as early as three months before becoming pregnant. Women in higher income households and with more years of school education are using more folic acid supplements before pregnancy. Women with planned pregnancies and who are over the age of 25 are more likely to use folic acid supplement. Canadian public health efforts are focused on promoting awareness of the importance of folic acid supplementation for all women of childbearing age and decreasing socio-economic inequalities by providing practical folic acid support to vulnerable groups of women. [98]

#### **New Zealand**

New Zealand was planning to fortify bread (excluding organic and unleavened varieties) from 18 September 2009, but has opted to wait until more research is done. [90]

The Association of Bakers [100] and the <u>Green Party</u> [101] have opposed mandatory fortification, describing it as "mass medication". Food Safety Minister Kate Wilkinson reviewed the decision to

fortify in July 2009, citing links between overconsumption of folate with cancer . [102] The New Zealand Government is reviewing whether it will continue with the mandatory introduction of folic acid to bread. [103]

#### **United Kingdom**

There has been previous debate in the <u>United Kingdom</u> regarding the inclusion of folic acid in products such as <u>bread</u> and <u>flour</u>. While the <u>Food Standards Agency</u> has recommended folic acid fortification, and wheat flour is fortified with iron, folic acid fortification of wheat flour is allowed voluntarily rather than required.

#### **United States**

The <u>United States Public Health Service</u> recommends an extra 0.4 mg/day for newly pregnant women, which can be taken as a pill. However, many researchers believe supplementation in this way can never work effectively enough, since about half of all pregnancies in the U.S. are unplanned, and not all women will comply with the recommendation. Approximately 53% of the US population uses dietary supplements and 35% uses dietary supplements containing folic acid. [108] Men consume more folate (in dietary folate equivalents) than women, and non-Hispanic whites have higher folate intakes than Mexican Americans and non-Hispanic blacks. [108] Twentynine percent of black women have inadequate intakes of folate. [108] The age group consuming the most folate and folic acid is the >50 group. [108] 5% of the population exceeds the Tolerable Upper Intake Level. [108]

In 1996, the United States <u>Food and Drug Administration</u> (FDA) published regulations requiring the addition of folic acid to enriched breads, cereals, flours, corn meals, pastas, rice, and other grain products. This ruling took effect on January 1, 1998, and was specifically targeted to reduce the risk of neural tube birth defects in newborns. There are concerns that the amount of <u>folate</u> added is insufficient. In October 2006, the Australian press claimed that U.S. regulations requiring fortification of grain products were being interpreted as disallowing fortification in non-grain products, specifically <u>Vegemite</u> (an Australian <u>yeast extract</u> containing folate). The FDA later said the report was inaccurate, and no ban or other action was being taken against Vegemite.

As a result of the folic acid fortification program, fortified foods have become a major source of folic acid in the American diet. The <u>Centers for Disease Control and Prevention</u> in <u>Atlanta</u>, <u>Georgia</u> used data from 23 birth defect registries covering about half of United States births, and extrapolated their findings to the rest of the country. These data indicate since the addition of folic acid in grain-based foods as mandated by the FDA, the rate of neural tube defects dropped by 25% in the United States. The results of folic acid fortification on the rate of neural tube defects in <u>Canada</u> have also been positive, showing a 46% reduction in prevalence of NTDs; the magnitude of reduction was proportional to the prefortification rate of NTDs, essentially removing geographical variations in rates of NTDs seen in <u>Canada</u> before fortification.

When the U.S. Food and Drug Administration set the folic acid fortification regulation in 1996, the projected increase in folic acid intake was 100  $\mu$ g/d. Data from a study with 1480 subjects showed that folic acid intake increased by 190  $\mu$ g/d and total folate intake increased by 323  $\mu$ g dietary folate equivalents (DFE)/d. Folic acid intake above the upper tolerable intake level (1000  $\mu$ g folic acid/d) increased only among those individuals consuming folic acid supplements as well as folic acid found in fortified grain products. Taken together, folic acid fortification has led to a bigger increase in folic acid intake than first projected.

#### See also

Levomefolic acid

## References

```
A R. M. C. Dawson: Data for Biochemical Research, Oxford University Press, Oxford, 1989, 3nt Edition, p. 134, ISBN 0-19-855299-8.

**Littal, Serdar H. (2008-11). "Folic Acid and Pregnancy." Kid's Health.

**Definition of Vitamin BC. Medical-dictionary, thefreedictionary, com. Retrieved 2012-09-09.

**Well, Andrew. "Supplements & Herbs (Vitamin B9.—Folate)". MD. www.drwell.com. Retrieved 4/2/14.

**Tolate." Patient Care & Health Info — Drugs and Supplements. Mayo Clinic. 1 November 2013. Retrieved 11 January 2014.

**Tolate." Patient Care & Health Info — Drugs and Supplements. Mayo Clinic. 1 November 2013. Retrieved 11 January 2014.

**Tolate." Policies. Patient Care & Health Info — Drugs and Supplements. Mayo Clinic. 1 November 2013. Retrieved 11 January 2014.

**Tolate." Policies. Policy (September 2009). "The extremely slow and variable activity of dihydrofolate reductase in human liver and its implications for high folic acid intake". Proceedings of the National Academy of Sciences of the United States of America 106 (36): 15424–9 Bibcode;2009PNAS., 10615424B.doi:10.1073/pnas.0902072106. PMC 2730961. PMID 19706381.

**A PLA State Vision St. All Anton T. J., Stotzenberg-Solomon R, et al. (November 2003. "Null association between prostate cancer and serum folate, vitamin B(6), vitamin B(12), and homocysteine." Cancer Epidemiol. Biomarkers Prev. 12(11 Pr.1): 1271–2. PMID 14652294.

**Picitary. Supplement Fact Cliffice of Diestry Supplements Association between prostate cancer and serum folate, vitamin B(6), vitamin B(6).
                               homocysteine*. Cancer Epidemiol. Biomarkers Piev. 12(11 Pt 1): 1271–2. PMID_14652294.

* "Dietary Supplement Fact Sheet: Folate*. Office of Dietary Supplements, National Institutes of Health.

* "Bietary Supplement fact Sheet: Folate*. Health Information. Office of Dietary Supplements, US National Institutes of Health. Retrieved 11 January 2014.
                             A 8 1 2 20 | Settler Supplement fact sheet: Folate', Health Information. Office of Dietary Supplements, US National Institutes of Health. Retrieved 11 January 2014.

Sentill et al., 2009. Folic Acid Deficiency http://emedicine.medscage.com/anticle/20184-0ven/ew

National Health Service U.K., "Anaemia, vitamin B12 or folate deficiency / Causes' <a href="http://www.ntsu.u/k/Conditions/Anaemia-vitamin-B12-and-folate-deficiency/anges/Causes.aspx">http://www.ntsu.u/k/Conditions/Anaemia-vitamin-B12-and-folate-deficiency/anges/Causes.aspx</a>

Shaw GM, Schaffer D, Velie EM, Morland K, Harris JA (May 1995). "Periconceptional vitamin use, dietary folate, and the occurrence of neural tube defects'. ** Epidemiology 6(3): 2' 26. doi:10.1097/0001648-198503500-00005.PMID 761926.

Mullinare J, Cordero JF, Erickson JD, Berry RJ (December 1988). "Periconceptional use of multivitamins and the occurrence of neural tube defects". ** JAMA 260 (21): 3141-

Mullinare J, Cordero JF, Erickson JD, Berry RJ (December 1988). "Periconceptional use of multivitamins and the occurrence of neural tube defects". ** JAMA 260 (21): 3141-

** Mullinare J, Cordero JF, Erickson JD, Berry RJ (December 1988). "Periconceptional use of multivitamins and the occurrence of neural tube defects". ** JAMA 260 (21): 3141-

** Mullinare J, Cordero JF, Erickson JD, Berry RJ (December 1988). "Periconceptional use of multivitamins and the occurrence of neural tube defects". ** JAMA 260 (21): 3141-

** Mullinare J, Cordero JF, Erickson JD, Berry RJ (December 1988). "Periconceptional use of multivitamins and the occurrence of neural tube defects". ** JAMA 260 (21): 3141-

** Mullinare JC ordero JF, Erickson JD, Berry RJ (December 1988). "Periconceptional use of multivitamins and the occurrence of neural tube defects". ** JAMA 260 (21): 3141-

** Mullinare JC ordero JF, Erickson JD, Berry RJ (December 1988). "Periconceptional use of multivitamins and the occurrence of neural tube defects". ** JAMA 260 (21): 3141-

** Mullinare JC ordero JF, Erickson JD, Berry RJ (D
 12.
13.
14.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             . Epidemiology 6(3): 219-
                           Abuliane 1, Cordero J.F. Enkoson J.D. Berry R.J. December 1989. "Periconceptional use of multivitamins and the occurrence of neural tube defects". JAMA 260 (21): 3141–5 doi:10.1001/jama.1986.03410210053035 PMID 3184392.

Millurasky A., Jück H., Jick S., Furell C., MacLaughlin DS, Rothman KJ, Willett W (1989). "Multivitamin/folic acid supplementation in early pregnancy reduces the prevalence of neural tube defects". Journal of the American Medical Association 262 (20): 2847–2852 doi:10.1001/jama.262.20.2847. PMID 2478730.

Willicox A.J. Lie RT, Solvoll K, et al. (March 2007). "Folic acid supplementation and risk of facial cellets: national pollation based case-control study". BMJ 334 (7591): 464. doi:10.1136/bmij.39079.618267.08. PMC 1808175. PMID 17259187.

ABC Good M, Koren G. (January 2008). "Folic acid: influence on the outcome of pregnancy". Am. J. Clin. Nutr. 71 (5 Suppl): 12955–3035. PMID 18259891.

Scholl TO, Johnson WG (May 2000). "Folic acid: influence on the outcome of pregnancy". Am. J. Clin. Nutr. 71 (5 Suppl): 12955–3035. PMID 1928392.

Wilton DC, Fourer MJ (June 2010). "As unevery of folic acid use in primigravid women". Women Brith 23 (2): 67–73. doi:10.1016/j.kmmbi.2009.09.001. PMID 1928392.

Wilton DC, Fourer MJ (June 2010). "As unevery of folic acid use in primigravid women". Women Brith 23 (2): 67–73. doi:10.1016/j.kmmbi.2009.09.001. PMID 1928392.

Wilton DC, Fourer MJ (June 2010). "As unevery of folic acid use in primigravid women". Women Brith 23 (2): 67–73. doi:10.1016/j.kmmbi.2009.09.001. PMID 1928392.

Wilton DC, Fourer MJ (June 2010). "As unevery of folic acid use in primigravid women". Women Brith 23 (2): 67–73. doi:10.1016/j.kmmbi.2009.09.001. PMID 1928392.

**Elealth Professionals Recommendations. Folic Acid. NCBDDD. CDC.

United States Department of Agriculture (USDA). 2010. Dietary Guidelines for Americans. 7th ed. Government Printing Office , Washington, DC, U.S.

**Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defect
 15.
 16.
                                                                   12. PMD 1522835.
ters for Disease Control (CDC) (August 1991). "Use of folic acid for prevention of spina bifida and other neural tube defects—1983-1991". MMWR Morb. Mortal. Wkly. Rep. 40(30): 513—
24.
                           ^ Centers for Disease Control (CDC) (August 1991). "Use of totic acid for prevention or spirit united shall outer inevient with control of programs of public and folia acid." Human Vitamin and Mineral Requirements.

A *** A *** Steegers: The unissen RP, Obermann-Borst SA, Kremer D, et al. (2009). "Perconceptional maternal folia acid use of 400 microg per day is related to increased methylation of the IGF2 gene in the very young child". In Zhang, Cullin. PLoS ONE 4 (11): e7845.doi:10.1371/journal.pone.0007845. PMC 2773848. PMID 19924280.

A ***CGUIR M. Cleary B, Sahm, L. Murphy DJ (February 2010). "Prevalence and predictors of perconceptional folia acid uptake—prospective cohort study in an Irish urban obstetric population". Hum. Reprod. 25 (2): 535–43 doi:10.1933/humrso/dep38. PMID 19910320.

Jia ZL, Lir, Chen CH, et al. (January 2010). "Association among polymorphisms at MYH9, environmental factors, and nonsyndromic ordical clefts in western China". DNA Cell Biol. 29 (1): 25–32. doi:10.1089/dna.2009.0335. PMID 19991592.

**BEBISCH. M. Thomas CM. Peters WH, Braza DD, Steepers-Theurissen RP (2007). The importance of foliate, zinc and antioxidants in the pathogenesis and prevention of subfertility". Hum. Reprod. Update 13 (2): 163–74. doi:10.1093/humpddmi054. PMID 170993205.

**Yajnik CS. Deshmukh US (September 2008). "Maternal nutrition, intrauterine programming and consequential risks in the offspring". Rev Endocr Metab Disord 9 (3): 203–11.doi:10.1007/s11154.008-9087z. PMID 18661241.

**Beard CM. Panser LA, Katuss CS K Uluy 2011). "Is excess folia acid supplementation a risk factor for autism?". Med. Hypotheses 77 (1): 15–7. doi:10.1016/j.mehy.2011.03.013. PMID 21454018.
27
28.
 29
 30
31
                             7.doi:10.1016/j.mehy.2011.03.013. PMID 21454018

A Jon Hamilton. Felia Acid Fur Pregnam Mothers (zus Kids Autism Rsk.* NPR. Retrieved 2013-03-08.

Tobes Folio Acid Help Prevent Autism? K. Retrieved 2013-07-25.

Altimibe S, Stavreus-Evers A, Rutz JR, et al., (June 2010). "Vanations in foliate pathway genes are associated with unexplained female infertility". Fertil. Steril. 94 (1): 130-7.doi:10.1016/j.fernister.2009.02.02.5 [PMD 19324355]

Bazzano LA (August 2011). "No effect of folis acid supplementation on cardiovascular events, cancer or mortality after 5 years in people at increased cardiovascular risk, although homocysteine levels are reduced." Evid Based Med 16 (1): 1178-d. doi:10.1136/ebm1204.PMID 21402567.

Bazzano LA (July 2009). "Folic acid supplementation and cardiovascular disease: the state of the art". Am. J. Med. Sci. 338 (1): 48-9. doi:10.1097/MAJ.b001363181 taaefde.PMID 19530140.
 32
33
34
 35
 36.
                                             Bazzian D.A. (July 2009). "Folic acid supplementation and cardiovascular disease: the state of the art". Am. J. Med. Sci. 338 (1): 48–9 doi:10.1097/MJJ.0b01981811aeafde.PMID 19593104.
"Folic acid 'reduces stroke risks". BBC News (London). 31 May 2007.
Terwecoren A., Steen E., Benoit D., Boon P., Hemelsoet D. (September 2009). "Ischemic stroke and hyperhomocysteinemia: truth or myth?". Acta Neurol Belg109 (3): 181–8. PMID 19902811.
Vollset, SE: Clarke, R., Lewington, S.; Ebbing, Mt. Halsey, J.; Lonn, E.; Armitage, J.; Manson, JE; Hankey, GJ; Spence, JD; Galan, P.; Banaa, KH; Jamison, R.; Gaziano, JM, Guarino, P.; Baron, JA; Logan, RF; Giovannucci, EL; den Heljer, M; Ueland, PM; Bennett, D; Collins, R; Peto, R; for the B-Vitamin Treatment Trialists', Collaboration (Jan 24. 2013). "Effects of folic acid supplementation on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50 000 individuals'. Lancer 381(9371): 1029–36. doi:10.1016/S0140-
                               StDpieritriaan's rovins and the state of the
41.
                             A Sanjoaquin MA, Allen N, Couto E, Roddam AW, Key TJ (February 2005). "Folate intake and colorectal cancer risk, a meta-analysis and epiperature of the property of the proper
 44.
45.
 46.
                               9.PMID 9713483.
^ Kepka I, De Lassence A, Ribrag V, et al. (March 1998). "Successful rescue in a patient with high dose methotrexate-induced nephrotoxicity and acute renal failure". Leuk.
                                               Lymphoma 29 (1–2): 205–30di:10.3109/10428199903063397. PMID 963991.
Branda RF. Nigels E, Lafayette AR, Hacker M. (1998). "Nutritional Tolate status influences the efficacy and toxid yof chemotherapy in rats". Blood 92 (7): 2471–6. PMID 97.46787.
Shiroky JBF, Frejoc (November 1997). "The use of foliates concomitantly with low-dose pulse methortexate". Rheum. Dis. Clin. North Am. 23 (4): 969–80. doi:10.1018/50889.
 48.
49.
                             50.
 51
 52.
                           ^ Taylor MJ, Carney SM, Goodwin GM, Geddes JR (June 2004). "Folate for depressive disorders: systematic review and meta-analysis of randomized controlled trials". J. Psychophama (Oxford) 18 (2): 251-8, doi:10.1177/20588110/042630. "DPMID 15260915".

Gilbody S, Lewis S, Lightfoot T (January 2007). "Methyleneterahydrofolate reductase (MTHFR) genetic polymorphisms and psychiatric disorders: a HuGE review". Am. J. Epidemiol. 165 (1): 1-13. doi:10.1033/aie/emw347_PMID 17074966.

Gilbody S, Lightfoot T, Sheldon T (July 2007). "Is low folate a risk factor for depression? A meta-analysis and exploration of heterogeneity". J Epidemiol Community Health 61 (7): 631−7. doi:10.1136/jech.2006.050385_PMC_2465760. PMID 17568057.

Gaweesth S, Ewiss AA (February 2010). Folic and Supplementation cures hot flushes in postmenopausal women". Med. Hypotheses 74 (2): 286–
53.
                           55.
56.
 57.
 58
59
                               ^ Diaz, V. H. US Patent 20080020071, Jan 24, 2008.

A B Malterre T (September 2009). "Digestive and nutritional considerations in celiac disease: could supplementation help?". Altern Med Rev 14 (3): 247–57. PMID 19803549. [International Considerations of the Constitution of the Constit
65.
66.
                               A Varela-Moreiras G, Murphy MM, Scott JM (May 2009). "Cobalamin, folic acid, and homocysteine". Nutr. Rev. 67 Suppl 1: S69–72. doi:10.1111/j.1753-4887.2009.00163.x PMID 19453682.
A Pasicha S, Shet A, Sachdev HP, Shet AS (October 2009). "Risks of routine iron and folic acid supplementation for young children". Indian Pediatr 46 (10): 857–66. PMID 19887691.
A © E'Dietary Supplement Fact Sheet: Folate". National Institutes of Health.
Owers, Janel E; Ciliford, Andrew J.; Barnforth, Charles W. (2007). "Folate in Beer". Journal of the Institute of Brewing 113 (3): 243–248. doi:10.1002/j.2050-
70
                           △ Owens, Janel E.; Clifford, Andrew J.; Bamforth, Charles W. (2007). "Foltate in Beer", Journal of the Institute of Brewing 113 (3): 243–248. doi:10.1002/j.2050-0416.2007. https://doi.org/10.2050/pub.23x.is.SSN 9046-9750.

△ Dietrich, M. Brown, C.; Block, G (2005). "The effect of folate fortification of cereal-grain products on blood folate status, dietary folate intake, and dietary folate sources among adult non-supplement users in the United States." J Am Coll Nutr 24 (4): 266–274 doi:10.1080/07315724.2005.10719474.PMID 16993404.

△ Suitor, C.W.; Bailey, L.B. (2000). "Dietary folate equivalents: interpretation and application". J Am Diet Assoc 100 (1): 88–94. doi:10.1016/S0002-8223(00)00027-4.PMID 10646010.

△ 2abanillas, M. Moya Chimenti, E.; Sonzález Candela, C.; Loria Kohen, V.; Dassen, C.; Lajo, T. (2009). "Usefulness of meal replacement: analysis of the principal meal replacement products commercialised in Spain". Nutr Hosp 24 (6): 555–42. PMID 19893863.

△ 2abanillas, M. Moya Chimenti, E.; Sonzález Candela, C.; Loria Kohen, V.; Dassen, C.; Lajo, T. (2009). "Usefulness of meal replacement: analysis of the principal meal replacement products commercialised in Spain". Nutr Hosp 24 (6): 555–42. PMID 19893863.

△ 2abanillas, M. Moya Chimenti, E.; Sonzález Candela, C.; Loria Kohen, V.; Dassen, C.; Lajo, T. (2009). "Usefulness of meal replacement: analysis of the principal meal replacement products commercialised in Spain". Nutr Hosp 24 (6): 555–42. PMID 19893133.

△ 2abanillas, M.; Moya Chimenti, E.; Sonzález Candela, C.; Loria Kohen, V.; Dassen, C.; Lajo, T. (2009). "Usefulness of meal replacement: analysis of the principal meal replacement products commercialised in Spain". Nutr Hosp 24 (6): 555–44. PMID 19893863.

△ 2abanillas, M.; Moya Chimenti, E.; Sonzález Candela, C.; Loria Kohen, V.; Dassen, C.; Lajo, T. (2009). "Usefulness of meal replacement: analysis of the principal meal replacement products commercialised in Spain". Nutr Hosp 24 (2009). "Chapter 30, 110.1016/20072-24. PMID 198936
                               8. Bibcode:1945Sci...102..227A.doi:10.1126/science.102.2644.227. PMID 17778509.

^ Figueiredo JC, Grau MV, Haile RW, et al. (March 2009). Folic acid and risk of prostate cancer: results from a randomized clinical trial". J. Natl. Cancer Inst. 101 (6): 432–
 79
```

- Alaimo K, McDowell MA, Briefel RR, Bischof AM, Caughman CR, Loria CM, Johnson CL (1994). "Dietary intake of vitamins, minerals, and fiber of persons ages 2 months and over in the United States: Third National Health and Nutrition Examination Survey, Phase 1, 1988–91". Advance Data from Vital and Health Statistics (258): 1–28. PMID 10138938.
   A Raiten DJ, Fisher KD (1995). "Assessment of folate methodology used in the Third National Health and Nutrition Examination Survey (NHANES III, 1988–1994)". The Journal of Nutrition 125 (5): 13715–13985. PMID 1738698.
   Lewis CJ, Crane NT, Wilson DB, Yetley EA (August 1999). "Estimated folate intakes: data updated to reflect food fortification, increased bioavailability, and dietary supplement use". Am. J. Clin. Nutr. 70 (2): 1982-07. PMID 10426955.
   Alaim 4 Global Progress". Flour Fortification Initiative website. Flour Fortification Initiative. November 2013.

- A\*B\*A\*\* Global Progress\*. Flour Fortification Initiative website. Flour Fortification Initiative. November 2013.
   A\*Bread afortification in pit. spidled.\*\* The Sydney Moming Herald. 29 July 2006.
   A\*B\*\*\* Read and Initiation from Initiative. November 2019.
   A\*Bread additive call by to NZ\*\*. Retrieved 2009-07-15.
   A\*Bread additive call by to NZ\*\*. Retrieved 2009-07-15.
   A\*French AE, Grant R, Weitzman S, et al. (September 2003). \*Folic acid food fortification is associated with a decline in neuroblastoma\*. Clin. Pharmacol. Ther. 74 (3): 288–94.doi:10.1016/S0009-9236(03)00200-5. PMID 12965372.
   A\*Ionescultur R, Marelli AJ, Mackle AS, Pilote L (2009). \*Prevalence of severe congenital heart disease after folic acid fortification of grain products: time trend analysis in Quebec, Canada\*. BMJ 338: 16f3\*, doi:10.1136/bmj.bf37. PMZ 2682153.PMID 1936079.
   A\*\* A\*\* A\*\* B\*\* Smith AD, Kim YI, Refsum H (March 2008). \*Folic acid good for everyone?\*. Am. J. Clin. Nutr. 87 (3): 517–33.PMID 18326588.
   Ulrich CM, Potter JD (February 2006). \*Folate supplementation: too much of a good thing?\*. Cancer Epidemiol. Biomarkers Prev. 15 (2): 189–93.doi:10.1158/1055-9965.EPI-15200.PMID 16492904.

- Linch CM, Jak H. D. February 2006). Foliate supplementation: too much of a good thing?" Cancer Epidemiol. Biomarkers Prev. 15 (2): 189–93. doi:10.1158/1055-9965.EPI-152CO. PMID 16425904.

  4 E Mason JB, Dickstein A, Jacques PF, et al. (July 2007). A temporal association between folic acid fortification and an increase in colorectal cancer rates may be illuminating important Abloquical principles: a hypothesis." Cancer Epidemiol. Biomarkers Prev. 16 (7): 1325–9 doi:10.1158/1055-9965.EPI-07-0329. PMID 17826997.

  4 Curilivan EP, Georgy JF (January 2003). Effect of food fortification on folic acid intake in the United States." Am. J. Clin. Nutr. 77 (1): 221–5. PMID 12499345.

  4 Pelecione to the Health Canada Web site. Hos.eq.cic. Retireved 2012-04-09.

  5 Chusticka, Z. (2009 Retrieved 11.09.). Mass Medication Plant (Press release). Association Of Bakers. 2009-07-03. Retrieved 2009-07-13.


  10 Nov. Starts on Wilkinson's Mass Medication Plant (Press release). Green Party. 2009-07-09. Retrieved 2009-07-13.

  10 Nov. Provide Plant Plant (Press Plant Pl

- 110. Dely S, Mills JL, Molloy AM, et al. (December 1997). "Minimum effective dose of folic acid for food fortification to prevent neural-rupe detects." Lancer 30 (2004). 1000–9. doi:10.1016/S0140-6736(97)07247-4. PMID 9400511.
  111. Crandall BF, Corson VL, Evans MI, Goldbeig JD, Knight G, Salafsky IS (July 1998). "American College of Medical Genetics statement on folic acid: fortification and supplementation". Am. J. Med. Genet. 78 (4): 381 doi:10.1002/(SICI)1096-8628(19980724)78-4-581;AID-AJM/G16-30.CQ2-E. PMID 9714444.
  112. A "EDA muffed chance to reduce birth defects." Boston Globe. G. January 2004.
  113. A "US denies Vegemite ban". 25 October 2006. Archived from the original on 2009-03-01.
  114. C Centers for Disease Control and Prevention (CDC) (May 2004). "Spina bifida and anencephaly before and after folic acid mandate—United States, 1995-1996 and 1999-2000". MMWR Morb. Mortal. Willy. Rep. 53 (17): 362-5 PMID 15129193.
  115. A De Wals P, Tairour F, Van Allen Mi, et al. (July 2007). "Reduction in neural-tube defects after folic acid fortification in Canada". N. Engl. J. Med. 357 (2): 135–42 doi:10.1056/NEJMon067103. PMID 17625125.
  116. A "A Example of Chance Mortal Additional Control and Prevention (CDC) (Value 2004). "Spina birth processing of the processing

- Nutr. 132 (9): 2792–8. PMID 12221247

# Methylcobalamine 1500 mcg + Folic Acid 5 mg + Methylcobalamin + VitaminD3 1000 I.U. Tablet



Methylcobalamine 15 carbanide; cobalt(3+); Acid 5 mg + Pyridoxine 3 mg + Vitamin 3

#### Clinical data

AHFS/Drugs.com <u>International Drug Names</u>

<u>Legal status</u> <u>OTC (US)</u>

Routes oral, sublingual, injection.

#### Identifiers

<u>CAS number</u> <u>13422-55-4</u>

ATC code B03BA05

PubChem CID 6436232

<u>UNII</u> <u>BR1SN1JS2W</u>

CHEMBL CHEMBL1697757

Chemical data

Formula  $\underline{\mathbf{C}}_{63}\underline{\mathbf{H}}_{91}\underline{\mathbf{CoN}}_{13}\underline{\mathbf{O}}_{14}\underline{\mathbf{P}}$ 

Mol. mass 1344.40 g/mol

**Methylcobalamin** (mecobalamin, MeCbl, or MeB<sub>12</sub>) is a <u>cobalamin</u>, a form of <u>vitamin B<sub>12</sub></u>. It differs from <u>cyanocobalamin</u> in that the cyanide is replaced by a <u>methyl group</u>. Methylcobalamin features an octahedral cobalt(III) centre. Methylcobalamin can be obtained as bright red

crystals. [2] From the perspective of <u>coordination chemistry</u>, methylcobalamin is notable as a rare example of a compound that contains metal-alkyl bonds. Nickel-methyl intermediates have been proposed for the final step of <u>methanogenesis</u>.

Methylcobalamin is equivalent physiologically to <u>vitamin</u>  $B_{12}$ , and can be used to prevent or treat pathology arising from a <u>lack of vitamin</u>  $B_{12}$  (<u>vitamin B12 deficiency</u>), such as <u>pernicious anemia</u>.

Methylcobalamin is also used in the treatment of <u>peripheral neuropathy</u>, <u>diabetic neuropathy</u>, and as a preliminary treatment for <u>amyotrophic lateral sclerosis</u>.

# Methylcobalamine 1500 mcg + Folic Acid 5 mg + Production Pyridoxine 3 mg + VitaminD3 1000 I.U. Tablet

Methylcobalamin can be produced in the laboratory by reducing <u>cyanocobalamin</u> with <u>sodium</u> borohydride in alkaline solution, followed by the addition of methyl iodide. [2]

# **Functions**

This <u>vitamer</u> is one of two active coenzymes used by vitamin  $B_{12}$ -dependent enzymes and is the specific vitamin  $B_{12}$  form used by <u>5-methyltetrahydrofolate-homocysteine</u> <u>methyltransferase</u> (MTR), also known as methionine synthase. [citation needed]

Methylcobalamin participates in the <u>Wood-Ljungdahl pathway</u>, which is a pathway by which some organisms utilize carbon dioxide as their source of organic compounds. In this pathway, methylcobalamin provides the <u>methyl group</u> that couples to carbon monoxide (derived from CO<sub>2</sub>) to afford <u>acetyl-CoA</u>. Acetyl-CoA is a derivative of acetic acid that is converted to more complex molecules as required by the organism. [3]

Methylcobalamin is produced by some <u>bacteria</u>. It plays an important role in the environment. In the environment, it is responsible for the <u>biomethylation</u> of certain <u>heavy metals</u>. For example, the highly toxic <u>methylmercury</u> is produced by the action of methylcobalamin. In this role, methylcobalamin serves as a source of " $CH_3^+$ ".

#### See also

- Cobamamide
- Cyanocobalamin
- <u>Hydroxocobalamin</u>
- Vitamin B12

# References

- 1. A.L. R. McDowell, <u>Vitamins in animal and human nutrition</u>
  2. A David Dophin. Preparation of the Reduced Forms of Vitamin B<sub>12</sub> and of Some Analogs of the Vitamin B<sub>12</sub> Coenzyme Containing a Cobalt-Carbon Bond. D.B. McComnick and L.D. Wright, Eds. 1971;Vol.
- XVIII:34-54.
  3. \_^Fontecilla-Camps, J. C.; Amara, P.; Cavazza, C.; Nicolet, Y.; Volbeda, A. (2009). "Structure—function relationships of anaerobic gas-processing metalloenzymes". *Nature* **460** (7257): 814–
- 822. doi:10.1038/nature08299. PMID 19675641. Pdit
  4. △Zenon Schneider, Andrzej Stroiński, Comprehensive B12; Chemistry, Biochemistry, Nutrition, Ecology, Medicine

# Pyridoxine

Pyrid	oxine <sup>III</sup>				
HO N  Methylcobalamine 1500 pcg - Felle ccid 5 mg + Pyridoxine 3 mg - VitananD3 1,000 I.U. Tablet					
IUPAC name					
4,5-Bis(hydroxymethyl)-2-methylpyridin-3-ol  Identifiers					
CAS number	65-23-6, 58-56-0 (HCI)				
<u>PubChem</u>	1054				
ChemSpider	1025				
<u>DrugBank</u>	<u>DB00165</u>				
<u>KEGG</u>	<u>D08454</u>				
ChEBI CHEBI:16709					
<u>ChEMBL</u>	CHEMBL1364				
ATC code	<u>A11HA02</u>				
<u>Jmol</u> -3D images	Image 1				
<u>SMILES</u>					
CC1=NC=C(C(=C10)CO)CO					

<u>InChI</u>					
<u>InChI</u> =1S/C8H11NO3/c1-5-8(12)7(4-11)6(3-10)2-9-5/h2,10-12H,3-4H2,1H3					
Key: LXNHXLLTXMVWPM-UHFFFAOYSA-N					
Properties					
Molecular formula	$C_8H_{11}NO_3$				
Molar mass	169.18 g mol <sup>-1</sup>				
Melting point	159-162 °C				
Except where noted otherwise, data are given for materials in their standard state (at 25 °C (77 °F), 100 kPa)					
TM Mouth					

**Pyridoxine** is one of the compounds that can be called <u>vitamin B<sub>6</sub></u>, along with <u>pyridoxal</u> and <u>pyridoxamine</u>. It differs from <u>pyridoxamine</u> by the substituent at the '4' position. Its <u>hydrochloride</u> saltp<u>yridoxine hydrochloride</u> is often used.

It is on the <u>World Health Organization's List of Essential Medicines</u>, a list of the most important medication needed in a basic health system. [2]

### Medicinal uses

Pyridoxine is given to patients taking <u>isoniazid</u> (INH) to combat the toxic side effects of the drug. It is given to people on isoniazide to prevent <u>peripheral neuropathy</u> and <u>CNS</u> effects that are associated with the use of INH.

Pyridoxine deficiency can lead to sideroblastic anemia.

It is also essential for patients with extremely rare <u>pyridoxine-dependent epilepsy</u>, thought to be caused by mutations in the ALDH7A1 gene.

In one form of homocystinuria, activity of the deficient enzyme can be enhanced by the administration of large doses of pyridoxine (100-1000 mg/day).

<u>Vitamin</u> B<sub>6</sub> can be compounded into a variety of different dosage forms. It can be used orally as a tablet, capsule, or solution. It can also be used as a nasal spray or for injection when in its solution form.

Vitamin  $B_6$  is usually safe at regular intakes. However, vitamin  $B_6$  can cause neurological disorders, such as loss of sensation in legs and imbalance, when taken in high doses over a long period of time. Vitamin  $B_6$  toxicity can damage sensory nerves, leading to numbness in the hands and feet as well as difficulty walking. Symptoms of a pyridoxine overdose may include poor coordination, staggering, numbness, decreased sensation to touch, temperature, and vibration, and tiredness for up to six months. One study reported that over a 6-month period or longer, 21% of women taking doses greater than 50 mg daily experienced neurological toxicity. The effect of doses below 50 mg was not reported. Pyridoxine's fetal safety is "A" in Briggs' Reference Guide to Fetal and Neonatal Risk. Is also used to treat a Vitamin B6 deficiency.

# Chemistry

It is based on a <u>pyridine</u> ring, with <u>hydroxyl</u>, <u>methyl</u>, and hydroxymethyl <u>substituents</u>. It is converted to the biologically active form <u>pyridoxal 5-phosphate</u>.

# Function in the body

Vitamin B<sub>6</sub> assists in the balancing of sodium and potassium as well as promoting red blood cell production. It is linked to cardiovascular health by decreasing the formation ofhomocysteine. Pyridoxine may help balance hormonal changes in women and aid the immune system. [6] Lack of pyridoxine may cause anemia, nerve damage, seizures, skin problems, and sores in the mouth. [7]

It is required for the production of

the monoamine neurotransmitters serotonin, dopamine, norepinephrine and epinephrine, as it is the precursor to pyridoxal phosphate: cofactor for the enzymearomatic amino acid decarboxylase. This enzyme is responsible for converting the precursors 5-hydroxytryptophan (5-HTP) into serotonin and melatonin, and levodopa (L-DOPA)

into dopamine, noradrenaline and adrenaline. As such it has been implicated in the treatment of depression and anxiety.

# Natural sources

Fish, soybeans, avocado, lima beans, chicken, bananas, cauliflower, green peppers, potatoes, spinach, raisins, brewer's yeast, blackstrap molasses, liver, kidney, heart. [8]

# References

- Pyridovine at Sigma-Aldrich

  "WHO Model List of EssentialMedicines". World Health Organization. October 2013. Retrieved 22 April 2014.

  "Vitamin B6 (pyridoxine) sources, benefits, dosage, deficiency, overdose, toxicity Vitamin B6 (pyridoxine) sources, benefits, dosage, deficiency, overdose, toxicity Vitamin B6 (pyridoxine) sources, benefits, dosage, deficiency, overdose, toxicity Vitamin B6 (pyridoxine) sources, benefits, dosage, deficiency, overdose, toxicity Vitamin B6 (pyridoxine) sources, benefits, dosage, deficiency, overdose, toxicity Vitamin B6 (pyridoxine) sources, benefits, dosage, deficiency, overdose, toxicity Vitamin B6 (pyridoxine) sources, benefits, dosage, deficiency, overdose, toxicity Vitamin B6 (pyridoxine) sources, benefits, dosage, deficiency, overdose, toxicity Vitamin B6 (pyridoxine) sources, benefits, dosage, deficiency, overdose, toxicity Vitamin B6 (pyridoxine) sources, benefits, dosage, deficiency, overdose, toxicity Vitamin B6 (pyridoxine) sources, benefits, dosage, deficiency, overdose, toxicity Vitamin B6 (pyridoxine) sources, benefits, dosage, deficiency, overdose, toxicity Vitamin B6 (pyridoxine) sources, benefits, dosage, deficiency, overdose, toxicity Vitamin B6 (pyridoxine) sources, benefits, dosage, deficiency, overdose, toxicity Vitamin B6 (pyridoxine) sources, benefits, dosage, deficiency, overdose, toxicity Vitamin B6 (pyridoxine) sources, benefits, dosage, deficiency, overdose, toxicity Vitamin B6 (pyridoxine) sources, benefits, dosage, deficiency, overdose, toxicity Vitamin B6 (pyridoxine) sources, benefits, dosage, deficiency, overdose, toxicity Vitamin B6 (pyridoxine) sources, benefits, dosage, deficiency, overdose, benefits, dosage, deficiency, overdose, and overdose, benefits, dosage, do
- Assinatian, wi, washina, N.; Jalamiran, S.; (2007), eylooxine (vitamin be) merapy for premenstrual syndrome . *international Journal of 4.* doi:10.1016/j.iigo.2006.90.14. PMID 171780144

  \[ \frac{\text{Vitamin B1}}{\text{Vitamin B1}}, www.HowStuffWorks.com? \]

  New Choice in Natural Healing, Rodale Press 1995